Wall Street Zen lowered shares of Zhongchao (NASDAQ:ZCMD – Free Report) from a sell rating to a strong sell rating in a research report sent to investors on Saturday,Wall Street Zen reports.
Separately, Weiss Ratings lowered Zhongchao from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, September 25th. One investment analyst has rated the stock with a Sell rating. According to MarketBeat, Zhongchao currently has an average rating of “Sell”.
Read Our Latest Research Report on Zhongchao
Zhongchao Price Performance
NASDAQ:ZCMD opened at $0.92 on Friday. The stock has a 50 day simple moving average of $1.57 and a 200 day simple moving average of $179.45. Zhongchao has a 1-year low of $0.91 and a 1-year high of $1,443.36.
Zhongchao Company Profile
Zhongchao Inc (NASDAQ: ZCMD) is a China-based healthcare services company focused on medical education and patient management. Through its operating subsidiaries, the company provides services intended to support healthcare professionals, patients and pharmaceutical or medical-product companies, with an emphasis on oncology and other chronic disease areas.
Zhongchao’s medical education activities have included online and offline educational programs, academic conferences, seminars and other professional training initiatives for physicians and healthcare providers.
See Also
- Five stocks we like better than Zhongchao
- AbbVie’s Humira Era Is Fading, But Its New Growth Engines Face Another Test
- GLP-1 Focus or Broader Peptide Exposure: Which ETF Has the Edge?
- Mortgage Rates Froze U.S. Housing, But These 3 Overseas Markets Still Pay Double Digits
- Big Tech Is Spending Billions on AI—These 5 Stocks Are Getting Paid
Receive News & Ratings for Zhongchao Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zhongchao and related companies with MarketBeat.com's FREE daily email newsletter.
